Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S364700
Reexamination Certificate
active
06933312
ABSTRACT:
This invention relates to pyrazole derivatives of formula (I)or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives.The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
REFERENCES:
patent: 0223232.0 (2002-10-01), None
patent: WO91/11172 (1991-08-01), None
patent: WO94/02518 (1994-02-01), None
patent: WO98/55148 (1998-12-01), None
patent: WO02/04424 (2002-01-01), None
patent: WO 02/30907 (2002-04-01), None
patent: WO02/34745 (2002-05-01), None
patent: WO 02/085860 (2002-10-01), None
U.S. Appl. No. 60/432,859, filed Dec. 11, 2002, Pfizer Inc.
Berge, et. al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences,1977, 1-19, vol. 66, No. 1.
Bighley, et. al., “Salt Forms of Drugs and Absorption,”Encyclopedia of Pharmaceutical Technology,Marcel Dekker Inc., 1996, 453-497, vol. 13, New York.
Bundgaard, et. al.,Design of Prodrugs,1985, Chapter 1, Elsevier Science Publishers, Amsterdam, New York, Oxford.
Ferres, et. al., “Pro-Drugs of β-Lactam Antibiotics,”Drugs of Today,1983, 499-538, vol. 19, No. 9.
Genin, et. al., “Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus the Delavirdine-Resistant P236L Mutant: Lead Indentification and SAR of 3- and 4-Substituted Derivatives,”Journal of Medicinal Chemistry,2000, 1034-1040, vol. 43, No. 5.
Greene, et. al.,Protecting Groups in Organic Synthesis,1991, Second Edition, John Wiley & Sons, New York, Chichester, Brisbane, Toronto, Singapore.
Katritzky, et. al., “The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds,”Comprehensive Heterocyclic Chemistry,1984, vol. 1-11, Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt.
Price David A.
Selby Matthew D.
Stupple Paul A.
Agouron Pharmaceuticals , Inc.
Hutchinson Keith D.
Richardson Peter C.
Solola Taofiq
Zielinski Bryan C.
LandOfFree
Pyrazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3480421